MA35439B1 - Inhibiteurs de l'enzyme activant nedd8 - Google Patents

Inhibiteurs de l'enzyme activant nedd8

Info

Publication number
MA35439B1
MA35439B1 MA36826A MA36826A MA35439B1 MA 35439 B1 MA35439 B1 MA 35439B1 MA 36826 A MA36826 A MA 36826A MA 36826 A MA36826 A MA 36826A MA 35439 B1 MA35439 B1 MA 35439B1
Authority
MA
Morocco
Prior art keywords
nedd8
inhibitors
activating enzyme
activating
enzyme
Prior art date
Application number
MA36826A
Other languages
English (en)
Inventor
Ashley Sue Mccarron
Todd B Sells
Matthew Stirling
Stephen G Stroud
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA35439B1 publication Critical patent/MA35439B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA36826A 2011-08-24 2014-03-13 Inhibiteurs de l'enzyme activant nedd8 MA35439B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161526830P 2011-08-24 2011-08-24
PCT/US2012/052007 WO2013028832A2 (fr) 2011-08-24 2012-08-23 Inhibiteurs de l'enzyme activant nedd8

Publications (1)

Publication Number Publication Date
MA35439B1 true MA35439B1 (fr) 2014-09-01

Family

ID=47747080

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36826A MA35439B1 (fr) 2011-08-24 2014-03-13 Inhibiteurs de l'enzyme activant nedd8

Country Status (29)

Country Link
US (3) US8809356B2 (fr)
EP (2) EP3323414A1 (fr)
JP (1) JP6038150B2 (fr)
KR (1) KR20140054288A (fr)
CN (1) CN103889988B (fr)
AR (1) AR087672A1 (fr)
AU (1) AU2012298813B2 (fr)
BR (1) BR112014004239A2 (fr)
CA (1) CA2846231C (fr)
CL (1) CL2014000441A1 (fr)
CO (1) CO6900148A2 (fr)
CR (1) CR20140128A (fr)
DO (1) DOP2014000037A (fr)
EA (1) EA031067B1 (fr)
EC (1) ECSP14013263A (fr)
GE (1) GEP201606522B (fr)
HK (1) HK1199252A1 (fr)
IL (1) IL231069B (fr)
MA (1) MA35439B1 (fr)
MX (1) MX2014002015A (fr)
MY (1) MY166889A (fr)
PE (1) PE20141146A1 (fr)
PH (1) PH12014500419A1 (fr)
SG (2) SG11201400102WA (fr)
TN (1) TN2014000080A1 (fr)
TW (1) TWI577667B (fr)
UA (1) UA114894C2 (fr)
UY (1) UY34292A (fr)
WO (1) WO2013028832A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
SG11201400102WA (en) * 2011-08-24 2014-03-28 Millennium Pharm Inc Inhibitors of nedd8-activating enzyme
CN104136399B (zh) 2012-02-17 2018-08-07 米伦纽姆医药公司 泛素活化酶的吡唑并嘧啶基抑制剂
JP2015524442A (ja) 2012-08-03 2015-08-24 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｕｂａ６のインドール置換ピロロピリミジニル阻害剤
EP2764866A1 (fr) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibiteurs de l'enzyme activant nedd8
CN105492429A (zh) * 2013-07-02 2016-04-13 米伦纽姆医药公司 Sumo活化酶的杂芳基抑制剂
CN103948590A (zh) * 2014-05-22 2014-07-30 中国药科大学 Nedd8激活酶抑制剂及其医药用途
BR112016030787B1 (pt) * 2014-07-01 2022-12-20 Takeda Pharmaceutical Company Limited Entidade química, composição farmacêutica e seu uso
KR101927375B1 (ko) * 2016-04-20 2018-12-11 한국화학연구원 신규한 헤테로고리 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2018213258A1 (fr) * 2017-05-15 2018-11-22 Millennium Pharmaceuticals, Inc. Traitement de tumeurs déficientes en merlin à l'aide d'inhibiteurs de nae
PT3792260T (pt) 2018-05-08 2024-10-02 Nippon Shinyaku Co Ltd Compostos de azabenzimidazol e produtos farmacêuticos
CA3161582A1 (fr) 2019-11-13 2021-05-20 Nippon Shinyaku Co., Ltd. Compose azabenzimidazole et medicament
WO2023025668A1 (fr) 2021-08-25 2023-03-02 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Méthodes pour la génération de lymphocytes t à mémoire de cellules souches pour une thérapie adoptive par lymphocytes t

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194446A (en) 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
AU6500696A (en) 1995-07-28 1997-02-26 Cubist Pharmaceuticals, Inc. Aminoacyl adenylate mimics as novel antimicrobial and antiparasitic agents
AU2003291024A1 (en) 2002-11-13 2004-06-03 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
EP1680431A1 (fr) 2003-10-17 2006-07-19 Rigel Pharmaceuticals, Inc. Compositions de benzothiazole et de thiazole'5,5-b!pyridine et leur utilisation comme inhibiteurs de l'ubiquitine ligase
US20050282818A1 (en) 2004-06-22 2005-12-22 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
PT1848718E (pt) 2005-02-04 2012-10-11 Millennium Pharm Inc Inibidores de enzimas de activação e1
KR101450535B1 (ko) 2006-02-02 2014-10-14 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｅ１ 활성화 효소의 억제제
EA201501088A1 (ru) * 2006-08-08 2017-01-30 Миллениум Фармасьютикалз, Инк. Гетероарильные соединения, применяемые в качестве ингибиторов e1 активирующих ферментов
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
SG175929A1 (en) 2009-05-14 2011-12-29 Millennium Pharm Inc Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
SG11201400102WA (en) * 2011-08-24 2014-03-28 Millennium Pharm Inc Inhibitors of nedd8-activating enzyme
KR101987861B1 (ko) * 2011-11-03 2019-06-11 밀레니엄 파머슈티컬스 인코퍼레이티드 Nedd-8 활성화 효소 억제제 및 저메틸화제의 투여

Also Published As

Publication number Publication date
JP2014524476A (ja) 2014-09-22
IL231069A0 (en) 2014-03-31
CL2014000441A1 (es) 2014-09-26
US9850214B2 (en) 2017-12-26
PH12014500419A1 (en) 2020-06-22
ECSP14013263A (es) 2014-04-30
UY34292A (es) 2013-04-05
SG10201601023UA (en) 2016-03-30
UA114894C2 (uk) 2017-08-28
WO2013028832A3 (fr) 2013-05-02
US20130150388A1 (en) 2013-06-13
EP3323414A1 (fr) 2018-05-23
IL231069B (en) 2018-02-28
AU2012298813A1 (en) 2013-05-02
CA2846231A1 (fr) 2013-02-28
KR20140054288A (ko) 2014-05-08
TW201313689A (zh) 2013-04-01
HK1199252A1 (en) 2015-06-26
MX2014002015A (es) 2014-03-27
NZ622220A (en) 2016-04-29
PE20141146A1 (es) 2014-09-21
AR087672A1 (es) 2014-04-09
GEP201606522B (en) 2016-08-10
CN103889988B (zh) 2018-05-04
BR112014004239A2 (pt) 2017-03-21
CO6900148A2 (es) 2014-03-20
MY166889A (en) 2018-07-24
DOP2014000037A (es) 2014-04-15
JP6038150B2 (ja) 2016-12-07
WO2013028832A2 (fr) 2013-02-28
EA201400249A1 (ru) 2014-05-30
SG11201400102WA (en) 2014-03-28
US20180290983A1 (en) 2018-10-11
CN103889988A (zh) 2014-06-25
US8809356B2 (en) 2014-08-19
EP2748168A2 (fr) 2014-07-02
AU2012298813B2 (en) 2016-07-28
EP2748168A4 (fr) 2015-04-22
CR20140128A (es) 2014-05-15
CA2846231C (fr) 2017-06-20
EA031067B1 (ru) 2018-11-30
TWI577667B (zh) 2017-04-11
US20150011572A1 (en) 2015-01-08
TN2014000080A1 (en) 2015-07-01

Similar Documents

Publication Publication Date Title
MA35439B1 (fr) Inhibiteurs de l'enzyme activant nedd8
EP2714970A4 (fr) Quantification d'enzyme
EP2726101A4 (fr) Inhibiteurs de l'activation des lymphocytes t
EP2729806A4 (fr) Utilisations d'inhibiteurs de hsp90 marqués
EP2683693A4 (fr) Inhibiteurs de rorgammat
HUE039849T2 (hu) CD70 elleni ellenanyagok
EP2776038A4 (fr) Inhibiteurs de l'acc et utilisations associées
EP2782570A4 (fr) Inhibiteurs hétérocycliques de glutaminase
EP2688568A4 (fr) Cyclopropylamines en tant qu'inhibiteurs de lsd1
EP2831279A4 (fr) Détection rapide d'aneuploïdie
EP2706852A4 (fr) Bipyridylaminopyridines en tant qu'inhibiteurs de syk
EP2788000A4 (fr) Pyrrolopyrimidines en tant qu'inhibiteurs de kinase janus
EP2670733A4 (fr) Inhibiteurs de hdac et procédés thérapeutiques les utilisant
IL225867B (en) Coelenterazine substrates
EP2903617A4 (fr) Inhibiteurs de l'activité de l'irak4
EP2707357A4 (fr) Pyridylaminopyridines en tant qu'inhibiteurs de syk
EP2799536A4 (fr) Inhibiteur de l'adhérence cellulaire
BR112015000507A2 (pt) inibição de enzimas
EP2764006A4 (fr) Sophorolipides modifiés pour l'inhibition de phytopathogènes
EP2685992A4 (fr) Amino-quinoléines en tant qu'inhibiteurs de kinase
PL2758371T3 (pl) Nowe tiopochodne niosące laktamy jako silne inhibitory hdac i ich zastosowania jako leki
PT2736340T (pt) Biocontrolo de nemátodos
EP2776564A4 (fr) Modulation de l'expression de tmprss6
EP2714694A4 (fr) Imides de bactériochlorines
LT3246325T (lt) 2-acilaminotiazolo junginio kristalai